ARA-290
ProtocolScheduling ARA-290 alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. An erythropoietin-derived peptide engineered to retain EPO's tissue-protective, anti-inflammatory effects without raising hematocrit. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.
Key Takeaways
Scheduling lens: ARA-290's ~2 min plasma; long tissue effect half-life via subq places it in the multi-daily-dosing bucket. Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Protocol calendar planning for ARA-290 is shaped by mechanism, pharmacokinetics, and operational reality. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any ARA-290 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most ARA-290 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
ARA-290 with a ~2 min plasma; long tissue effect half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.
Cycle length and off-cycle planning
Standard ARA-290 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
For stack scheduling scheduling, ARA-290 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for ARA-290 in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for ARA-290 in off-time starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For periodised cycles scheduling, ARA-290 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 2 mg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 4 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 3 mg | Ongoing with periodic pauses |
Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- ARA-290 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with ARA-290's mechanism in protocol / scheduling / cycling protocols.
- ARA-290 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with ARA-290's mechanism in protocol / scheduling / cycling protocols.
- ARA-290 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with ARA-290's mechanism in protocol / scheduling / cycling protocols.
- ARA-290 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with ARA-290's mechanism in protocol / scheduling / cycling protocols.
Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.
Lens-specific safety considerations for protocol / scheduling / cycling use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| ARA-290 | EPO-derived tissue-protective peptide | ~2 min plasma; long tissue effect | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for ARA-290?
Cycle length and off-cycle period?
Can I shift my schedule with travel?
When to integrate ARA-290 into an existing stack?
How do I schedule ARA-290 alongside my existing stack?
How does ARA-290's half-life affect dosing?
Start a ARA-290 Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified ARA-290 and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 1257 Da
- Sequence length
- 11 aa
- Half-life
- ~2 min plasma; long tissue effect
- WADA
- Not specifically listed (EPO analogues require care)
- FDA
- Unapproved (Phase II/III in sarcoidosis & neuropathy)
- Research
- Multiple Phase II human trials
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for ARA-290
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised